Oncormed gets patent for new BRCA1 mutation:
This article was originally published in Clinica
Oncormed has received a US patent covering a new mutation of the BRCA1 gene. The patent rights include therapeutics, diagnostic products and diagnostic services. Oncormed has already received two BRCA1-related US patents, each covering a full-length coding sequence of the BRCA1 gene which encodes for the normal or healthy BRCA1 protein. The US company recently licensed its diagnostic services rights in BRCA1 exclusively and BRCA2 non-exclusively to US competitor Myriad Genetics for use in its BRACAnalysis genetic testing service (see Clinica No 809, p19).
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.